MVA-BN smallpox vaccine clinical trials
Also written IMVAMUNE and MVA-BN.
How each study uses MVA-BN smallpox vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 4 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 15
Bavarian Nordic (14) · National Institute of Allergy and Infectious Diseases (NIAID) (11) · McMaster University (1) · Centers for Disease Control and Prevention (1) · Janssen Research & Development, LLC (1) · Sanofi Pasteur, a Sanofi Company (1) · Muhimbili University of Health and Allied Sciences (1) · Ivan Litvinov (1)
Often tested with
Tested in the same studies.
Shingrix (1) · Lipopolysaccharides (1) · Candida albicans Antigen Injection (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test MVA-BN smallpox vaccine.
- Nov 2026Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsPhase 2 · Bavarian Nordic
Studies
Open first, then newest update. How each study uses MVA-BN smallpox vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 31
- Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCTActive, not recruitingPhase 4McMaster UniversityNCT05745987Written as Bavarian Nordic smallpox vaccine
- JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the CongoCompletedPhase 3Centers for Disease Control and PreventionNCT02977715Written as JYNNEOS (Liquid Formulation)
- Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox VaccineCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05512949Written as JYNNEOS
- Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsActive, not recruitingPhase 2Bavarian NordicNCT07199569Written as Jynneos
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for MpoxCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05740982Written as JYNNEOS
- Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRCCompletedPhase 4National Institute of Allergy and Infectious Diseases (NIAID)NCT05734508Written as MVA-BN vaccine
- Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus InfectionsActive, not recruitingPhase 2Bavarian NordicNCT06549530Written as MVA-BN
- MVA Post-Event: Administration Timing and Boost StudyCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00437021Written as MVA Smallpox Vaccine
- High Dose IMVAMUNE® in Vaccinia-Naive IndividualsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00879762Written as MVA Smallpox Vaccine
- A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy ParticipantsCompletedEarly Phase 1Janssen Research & Development, LLCNCT03953196Written as Imvanex
- Imvamune Vaccine for the Treatment of Non-melanoma Skin CancerTerminatedPhase 1/2Ivan LitvinovNCT04410874Written as Imvamune
- Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00301184Written as Modified vaccinia Ankara/HIV62
- Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered IntradermallyCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00914732Written as MVA Smallpox Vaccine
- Special Access Program IMVAMUNE®CompletedPhase 4Bavarian NordicNCT03472014Written as IMVAMUNE®
- Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV InfectionCompletedPhase 2Bavarian NordicNCT02038881Written as IMVAMUNE®
- An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 VaccineesCompletedPhase 2Bavarian NordicNCT00686582Written as IMVAMUNE
- A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy SubjectsCompletedPhase 2Bavarian NordicNCT00316524Written as MVA-BN® (IMVAMUNE)
- Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic DisordersCompletedPhase 1Bavarian NordicNCT00189917Written as IMVAMUNE (MVA-BN)
- Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.CompletedPhase 2Bavarian NordicNCT00189956Written as IMVAMUNE (MVA-BN)
- A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced SubjectsCompletedPhase 2Bavarian NordicNCT00857493Written as IMVAMUNE
See all 31 studies that test MVA-BN smallpox vaccine →
Given beside what is tested · 3 — MVA-BN smallpox vaccine is usual care or a partner of the new treatment
- Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug UseRecruitingPhase 4University of Alabama at BirminghamNCT06829238Written as Jynneos
- A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®CompletedPhase 3Bavarian NordicNCT01913353Written as MVA BN®
- A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and MozambiqueCompletedPhase 2Muhimbili University of Health and Allied SciencesNCT01697007Written as Modified Vaccinia Ankara (MVA-CDMR)
As the comparator · 2 — what is tested is compared with MVA-BN smallpox vaccine
- Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the CongoNot yet recruitingPhase 2Shanghai Institute Of Biological ProductsNCT07253675Written as MVA-BN
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02743455Written as MVA Smallpox Vaccine
Codes
What other systems call MVA-BN smallpox vaccine · ClinicalTrials.gg INT005249
- MeSH (NLM) C527606smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordicConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) TU8J357395VACCINIA VIRUS MODIFIED STRAIN ANKARA-BAVARIAN NORDIC NON-REPLICATING ANTIGENConfirmed FDA, NLM, Wikidata
- Wikidata Q18358151MVA-BN smallpox vaccineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C173552MVA-BN Smallpox VaccineConfirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C527606 | smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | TU8J357395 | VACCINIA VIRUS MODIFIED STRAIN ANKARA-BAVARIAN NORDIC NON-REPLICATING ANTIGEN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q18358151 | MVA-BN smallpox vaccine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C173552 | MVA-BN Smallpox Vaccine | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.